8-K: Precigen Secures $79 Million in Private Placement, Advances PRGN-2012 BLA Submission

Precigen has successfully completed a $79 million private placement and submitted a Biologics License Application (BLA) to the FDA for PRGN-2012, a potential treatment for recurrent respiratory papillomatosis.

Summary

• Precigen has entered into a securities purchase agreement for a private placement of its 8.00% Series A Convertible Perpetual Preferred Stock, raising gross proceeds of $79 million before expenses.
• The private placement includes warrants to purchase 52,666,669 shares of common stock at an exercise price of $0.75 per share.
• The offering is expected to close on or before December 30, 2024.
• The net proceeds will be used for working capital and general corporate purposes.
• Precigen expects the financing, along with existing cash, to extend its cash runway well into 2026, beyond the anticipated commercial launch of PRGN-2012 in the second half of 2025, if approved.
• Dividends on the preferred stock will be paid annually in cash, but for the first two years, they will be paid in kind, increasing the liquidation preference and including warrants for additional common stock.
• The preferred stock is redeemable for cash at Precigens option and convertible into common stock at the holders option after six months, subject to shareholder approval.
• The company has also completed the submission of a BLA to the FDA for PRGN-2012, requesting priority review.
• The BLA is supported by data from a Phase 1/2 study where more than 50% of patients achieved Complete Response and more than 85% had a decrease in surgical interventions after treatment.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful private placement, the BLA submission, and the promising clinical trial results. The company's financial position is strengthened, and a potential commercial launch is on the horizon. However, there are some risks and uncertainties associated with the private placement and regulatory approvals.

Positives

• The $79 million private placement significantly strengthens Precigens financial position.
• The extended cash runway into 2026 provides financial stability for the company.
• The BLA submission for PRGN-2012 is a major milestone for the company.
• The positive results from the Phase 1/2 study of PRGN-2012 are encouraging.
• The potential for priority review by the FDA could expedite the approval process for PRGN-2012.
• The company has secured participation from key investors, including Randal J. Kirk and Bill Miller.

Negatives

• The preferred stock dividends for the first two years will be paid in kind, which may dilute existing shareholders.
• The conversion price of the preferred stock is subject to upward adjustment based on the valuation of the common stock.
• The private placement was conducted without a placement agent, underwriter, broker or dealer, which may have limited the reach of the offering.

Risks

• The private placement is subject to customary closing conditions and may not close as expected.
• The company has broad discretion in the use of proceeds from the private placement.
• There is no guarantee that the FDA will grant priority review for the PRGN-2012 BLA.
• The commercial launch of PRGN-2012 is subject to FDA approval and may be delayed.
• The company is subject to risks and uncertainties related to its business, as detailed in its SEC filings.

Future Outlook

Precigen anticipates a potential commercial launch of PRGN-2012 in the second half of 2025, pending FDA approval, and expects its current financing to extend its cash runway well into 2026.

Management Comments

• Helen Sabzevari, PhD, President and CEO of Precigen, stated that the BLA submission is an extremely important step in bringing the first therapy to fight RRP.
• She also mentioned that the recent financial transactions have enhanced the balance sheet and extended the cash runway into 2026.

Industry Context

The announcement highlights Precigens progress in the gene and cell therapy space, particularly in addressing rare diseases like recurrent respiratory papillomatosis. The successful BLA submission and private placement position the company to potentially become a leader in this niche market.

Comparison to Industry Standards

• The private placement is a common method for biotech companies to raise capital, especially those in the clinical stage.
• The use of convertible preferred stock and warrants is a typical structure for such financings.
• The BLA submission for PRGN-2012 is a significant step, as there are currently no approved therapies for RRP.
• The Phase 1/2 study results, with over 50% of patients achieving Complete Response, are promising compared to the current standard of care, which is repeated surgeries.
• The request for priority review is a strategic move to expedite the approval process, which is common for therapies targeting unmet medical needs.

Related Party Transactions

• Randal J. Kirk, executive chairman of the board of directors of Precigen, participated in the private placement.

Stakeholder Impact

• Shareholders: The private placement may cause dilution, but the extended cash runway and potential commercial launch of PRGN-2012 are positive.
• Employees: The financial stability and progress in clinical development may boost employee morale.
• Patients: The BLA submission for PRGN-2012 offers hope for a new treatment option for RRP.
• Investors: The private placement provides an opportunity to invest in a company with promising technology and a potential commercial product.

Next Steps

• The company will work to close the private placement on or before December 30, 2024.
• The company will await the FDA's decision on the acceptance of the BLA for PRGN-2012 and the granting of priority review.
• The company will continue to advance the development of PRGN-2012 and other therapies in its pipeline.
• The company will seek shareholder approval for the issuance of shares related to the private placement.

Key Dates

Keywords

private placement, convertible preferred stock, warrants, PRGN-2012, recurrent respiratory papillomatosis, BLA, FDA, gene therapy, biopharmaceutical, cash runway